Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

NCT04070040 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Camrelizumab

Sponsor

Beijing Sanbo Brain Hospital